This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arrayit Corporation To Work With Diagnostic Oncology Research Organization (DOCRO) To Obtain FDA Approvals

Stocks in this article: ARYC

Arrayit Corporation (ARYC) announced today that the company has signed a Professional Services Master Agreement (PSMA) with Diagnostic Oncology Research Organization (DOCRO, Inc.). Arrayit and DOCRO will use the PSMA as a blueprint for the submission and approval of the company's OvaDx® Pre-Symptomatic Ovarian Cancer Monitoring and Screening Test, as well as a secondary Parkinson’s Diagnostic Test and other pipeline tests.

Arrayit is a life sciences and molecular diagnostics company engaged in the business of commercializing in vitro diagnostic (IVD) medical devices used to detect and monitor a variety of medical disorders. The company uses microarray-based methods and systems to detect protein and nucleic acid biomarkers useful as aids in the detection, diagnosis, monitoring, therapy effectiveness determination, and prognosis of a variety of medical disorders, diseases, and conditions. As previously announced, Arrayit will utilize DOCRO-facilitated CLIA and ISO 9001 and ISO 13485 certified laboratories in its new company headquarters in Sunnyvale, California, USA for the OvaDx® and PDx™ FDA submission processes and for processing patient test samples upon FDA approval and commercialization.

DOCRO provides professional services to life sciences, diagnostics, biotechnology, therapeutic, medical device, and IVD medical device manufacturers and users of such devices such as clinical testing laboratories, in the form of tactical and strategic advice related to marketing claims, reimbursement, and regulatory requirements including the design and conduct of clinical trials with the United States Food and Drug Administration (FDA). DOCRO has assisted companies in more than 100 IVD clinical trials, and has secured more than 50% of the premarket approval (PMA) certifications for the entire IVD industry in the past 17 years with an unparalleled 100% FDA track record.

About Arrayit Corporation

Arrayit utilizes its patented and proprietary microarray platform to lead and empower the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs